Recombinant Human Anti-IAV HA Antibody (5J8) (CAT#: PABL-207)

Figure 1 Therapeutic efficacy of MAb 5J8 against disease caused bythe 1918 influenza A(H1N1) virus in mice.

Mice were inoculated onday 0 and treated on day 1 with the indicated antibody and dose. In each group, six mice were monitored every other day for survival.

Krause, J. C., Tsibane, T., Tumpey, T. M., Huffman, C. J., Basler, C. F., & Crowe, J. E. (2011). A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. Journal of virology, 85(20), 10905-10908.

Figure 1 Recombinant Human Anti-IAV HA Antibody (PABL-207) in SDS-PAGE

SDS-PAGE analysis of PABL-207 in non-reduced and reduced conditions.

Figure 2 Recombinant Human Anti-IAV HA Antibody (5J8) (PABL-207) in SEC-HPLC

The purity of PABL-207 was greater than 95% as determined by SEC-HPLC

Figure 3 Recombinant Human Anti-IAV HA Antibody (5J8) (PABL-207) in ELISA

ELISA analysis of PABL-207 was performed by coating with Influenza A H1N1 (A/California/04/2009) Hemagglutinin / HA Protein (His Tag).

The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 4 Recombinant Human Anti-IAV HA Antibody (5J8) (PABL-207) in WB

Western blot analysis of PABL-207 was performed with Influenza A H1N1 (A/California/04/2009) Hemagglutinin / HA Protein (His Tag).
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 5 Recombinant Human Anti-IAV HA Antibody (5J8) (PABL-207) in Dot Blot

Dot Blot analysis of PABL-207 was performed with Influenza A H1N1 (A/California/04/2009) Hemagglutinin / HA Protein (His Tag).
The secondary antibody: HRP-Anti-Human IgG (H+L)